Portfolio Management in New Drug Development - Innovation and Marketing in the Pharmaceutical Industry - page 114

literature on how NCATS can facilitate experimentation in innovative approaches to
develop new models of drug development and delivery. For instance, interactions
across disease categories will be a critical issue as therapeutics of the future may not
be limited by historical designations. The areas targeted by NCATS include thera-
peutic target validation, chemistry, virtual drug design, preclinical toxicology, bio-
markers, efficacy testing, phase zero clinical trials, rescuing, repurposing, clinical
trial design, and post-marketing research (Collins 2011 ). With over $720 million in
annual research support, NCATS presents a new opportunity for researchers to col-
laborate across disciplines to address varied challenges.
As can be seen, there exist a number of open questions for future research on
pharmaceutical portfolio management, both on the theoretical and empirical fronts.
We hope this review of current work on the topic will spur researchers across mul-
tiple disciplines to bring state-of-the-art methodologies to address these key issues.
References
Aaker DA, Tyebjee TT (1978) A model for the selection of interdependent R & D projects. IEEE
Trans Eng Manag 25(2):30-36
Ahn MJ, Zwikael O, Bednarek R (2010) Technological invention to product innovation: a project
management approach. Int J Proj Manag 28(6):559-568
Ali A, Kalwani MU, Kovenock D (1993) Selecting product development projects: pioneering ver-
sus incremental innovation strategies. Manag Sci 39(3):255-274
Amburgey TL, Kelly D, Barnett WP (1993) Resetting the clock: the dynamics of organizational
change and failure. Adm Sci Q 38(1):51-73
Argyres NS, Silverman BS (2004) R&D, organizational structure, and the development of corpo-
rate technological knowledge. Strateg Manag J 25:929-958
Baker N, Freeland J (1975) Recent advances in R&D benefit measurement and project selection
methods. Manag Sci 21(10):1164-1175
BiotechLive.com (2011) The CEDD is dead. Long live the TAU. http://www.biotechlive.
com/?p=168 . Accessed Sept 2011
Black F (1972) Capital market equilibrium with restricted borrowing. J Bus 45(3):444-455
Black F, Scholes M (1973) The pricing of options and corporate liabilities. J Polit Econ
81(3):637-654
Blau GE, Pekny JF, Varma VA, Bunch PR (2004) Managing a portfolio of interdependent new
product candidates in the pharmaceutical industry. J Prod Innov Manag 21(4):227-245
Chao RO, Kavadias S (2008) A theoretical framework for managing the new product development
portfolio: when and how to use strategic buckets. Manag Sci 54(5):907-921
Chao RO, Kavadias S, Gaimon C (2009) Revenue driven resource allocation: funding authority,
incentives, and new product development portfolio management. Manag Sci
55(9):1556-1569
Chao RO, Lichtendahl KC Jr, Grushka-Cockayne Y (2011) Incentives for complex R&D projects.
Working Paper
Childs PD, Triantis AJ (1999) Dynamic R&D investment policies. Manag Sci 45(10):1359-1377
Collins FS (2011) Reengineering translational science: the time is right. Sci Transl Med 3:1-6
Cooper RG, Edgett SJ, Kleinschmidt EJ (1998) New product portfolio management: practices and
performance. J Prod Innov Manag 16:333-351
Czajkowski AF, Jones S (1986) Selecting interrelated R&D projects in space technology planning.
IEEE Trans Eng Manag 33(1):17-24